Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 16/20 | 0.79 |
| ▸ | GABRB3 | P28472 | 16/20 | 0.79 |
| ▸ | GABRA3 | P34903 | 15/20 | 0.79 |
| ▸ | GABRA2 | P47869 | 12/20 | 0.76 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.76 |
| ▸ | GABRA1 | P14867 | 10/20 | 0.76 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.76 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.76 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10045479 | 0.92 | GABRG2 (0.77) | GABRG2GABRB3GABRA3GABRA2GABRA5 | |
| SCHEMBL637991 | 0.92 | GABRA3 (0.74) | GABRG2GABRB3GABRA3GABRA2GABRA5 | |
| SCHEMBL639291 | 0.92 | GABRG2 (0.74) | GABRG2GABRB3GABRA3GABRA2GABRA5 | |
| SCHEMBL16638525 | 0.90 | GABRG2 (0.74) | GABRG2GABRB3GABRA3GABRA2GABRA5 | |
| SCHEMBL13976094 | 0.89 | GABRG2 (0.73) | GABRG2GABRB3GABRA3GABRA2GABRA5 | |
| SCHEMBL13835287 | 0.89 | GABRA3 (0.73) | GABRG2GABRB3GABRA3GABRA2GABRA5 | |
| SCHEMBL637638 | 0.88 | GABRG2 (0.77) | GABRG2GABRB3GABRA3GABRA2GABRA5 | |
| SCHEMBL13966606 | 0.88 | GABRA3 (0.76) | GABRG2GABRB3GABRA3GABRA2GABRA5 | |
| SCHEMBL13061667 | 0.88 | GABRA3 (1.00) | GABRG2GABRB3GABRA3GABRA2GABRA5 | |
| SCHEMBL638802 | 0.87 | GABRA3 (0.67) | GABRG2GABRB3GABRA3GABRA2GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490344-B1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC SIDE EFFECTS | WISYS TECHNOLOGY FOUND INC (US) | 2008-03-19 | — | — | EP | claimed |
| US-RE47475-E1 | Selective agents for pain suppression | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-9597342-B2 | GABAergic receptor subtype selective ligands and their uses | UWM RESEARCH FOUNDATION, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9597342-B2 | GABAergic receptor subtype selective ligands and their uses | UWM RESEARCH FOUNDATION, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150258128-A1 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES | UWM RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150258128-A1 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES | UWM RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
| US-9006233-B2 | Gabaergic receptor subtype selective ligands and their uses | UWM RESEARCH FOUNDATION, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006233-B2 | Gabaergic receptor subtype selective ligands and their uses | UWM RESEARCH FOUNDATION, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20090093466-A1 | Carboxamide GABAa ALPHA2 Modulators | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-09 | — | — | US | disclosed |
| EP-1925614-A1 | Anxiolytic agents with reduced sedative and ataxic effects | Wisys Technology Foundation, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1490344-B1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC SIDE EFFECTS | WISYS TECHNOLOGY FOUND INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20070299058-A1 | Anxiolytic Agents With Reduced Sedative And Ataxic Effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7235656-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2006004945-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2003082832-A2 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | GABRG2 14/4885GABRB3 7/4885GABRA3 1/4885 |
| US-20090093466-A1 | Carboxamide GABAa ALPHA2 Modulators | GABRA2, GABRB2, GABRB1 | GABRG2 12/4885GABRB3 7/4885GABRA3 9/4885 |
| US-20150258128-A1 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES | GABRA3, GABRA2, GABRB3 | GABRG2 10/4885GABRB3 3/4885GABRA3 1/4885 |
| US-20070299058-A1 | Anxiolytic Agents With Reduced Sedative And Ataxic Effects | GABRA3, GABRA2, GABRA1 | GABRG2 14/4885GABRB3 7/4885GABRA3 1/4885 |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | GABRG2 14/4885GABRB3 7/4885GABRA3 1/4885 |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | GABRA3, GABRA6, GABRA4 | GABRG2 14/4885GABRB3 8/4885GABRA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.